Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATINEE: Mepolizumab in COPD with Frequent Exacerbations
NCT04133909Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2019
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of mepolizumab in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Oct 2019; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04133909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133909.